Tofacitinib reached musculoskeletal safety endpoints in PsA

11:37 EDT 15 Jun 2017 | Healio

MADRID — Two different dosing levels of tofacitinib bested placebo in response rate and safety parameters for patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress.“This is the first report of a clinical trial restricted to patients with [psoriatic arthritis] PsA and an inadequate response to a [tumor necrosis factor] TNF inhibitor,” Dafna D. Gladman, MD, of the Department of Medicine at the University of Toronto and Toronto Western Hospital in Canada, said. “The primary endpoint was achieved. Efficacy was maintained through 6 months. Tofacitinib may represent one of the potential novel treatments for PsA patients who have failed TNF inhibitors.”

Original Article: Tofacitinib reached musculoskeletal safety endpoints in PsA


More From BioPortfolio on "Tofacitinib reached musculoskeletal safety endpoints in PsA"

Quick Search


Relevant Topics

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...